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Approximately ten million people suﬀer from Chagas disease worldwide, caused by Trypanosoma cruzi, with the disease burden
predominately focused in Latin America. Sleeping sickness is another serious health problem, caused by Trypanosoma brucei,
especiallyinsub-Saharancountries.Unfortunately,thedrugscurrently availabletotreatthesediseaseshavetoxiceﬀects andarenot
eﬀective against all disease phases or parasite strains. Therefore, there is a clear need for the development of novel drugs and drug
targets to treat these diseases.Weproposethe trypanosomeprereplication machinery component,Orc1/Cdc6, asa potentialtarget
for drug development. In trypanosomes, Orc1/Cdc6 is involved in nuclear DNA replication, and, despite its involvement in such
a conserved process, Orc1/Cdc6 is distinct from mammalianOrc1 and Cdc6 proteins. Moreover, RNAi-mediated silencing of try-
panosomeOrc1/Cdc6expressioninT. brucei decreased cell survival,indicatingthatOrc1/Cdc6iscriticalfortrypanosomesurvival.
1.Introduction
Currently, approximately ten million people have Chagas
disease worldwide, with the disease burden being centered in
Latin America. In 2008, approximately ten thousand people
died from this disease. Sleeping sickness is another serious
health problem, particularly in sub-Saharan countries; in the
ﬁrst half of the twentieth century, this disease practically
decimated entire communities in central Africa [1]. After
many surveillance programs, 2009 marked the ﬁrst time in
50 years that less than ten thousand new cases of sleeping
sickness were reported in Africa (http://www.who.org/).
The causal agentsof Chagas disease and sleeping sickness
are, respectively, the protozoan parasites Trypanosoma cruzi
andT. brucei oftheKinetoplastidaorder.TwosubspeciesofT.
brucei, T. b. rhodesiense,a n dT. b. gambiense, are responsible
for acute sleeping sickness in Eastern and Southern Africa
and chronic sleeping sickness in Western and Central
Africa, respectively. Chronic sleeping sickness accounts for
approximately 95% of all reported cases.
These protozoa have life cycles that alternate between a
mammalian host and an insect host. T. cruzi epimastigotes
are a noninfective life cycle stage of the parasite that prolifer-
ate by binary ﬁssion in the guts of Triatoma infestans insects,
which are more commonly known as kissing bugs. These
epimastigotes then transform into the infective metacyclic
form in the insect hindgut. Then, when the insect vector
bites a mammalian host, they eliminate the metacyclic
parasites in their feces. This allows the parasites to penetrate
the wounded skin and enter into the mammalian host’s
circulatory system. Within the bloodstream, the metacyclic
parasites transform into trypomastigotes, which then infect
mammalian cells and transform into amastigotes. Amastig-
otes are spherically shaped and proliferate inside the infected
cells until transforming into nonreplicative trypomastigotes.
The life cycle is completed when an insect vector bites
an infected mammalian host and takes up trypomastigotes
within the blood that then transform into epimastigotes
inside the insect gut.
In contrast to T. cruzi, the life cycle of T. brucei spp.
is entirely extracellular. In this case, an infected tsetse
ﬂy (Glossina genus) bites a mammalian host, transferring
metacyclic trypomastiogte forms into the circulatory sys-
tem.Metacyclictrypomastiogtes transformintobloodstream2 Enzyme Research
trypomastigotes that then proliferate in the hemolymphatic
system as trypomastigotes, which are slender in form; next,
the parasites transform in a non-proliferative form that
is stumpy in appearance. When a new tsetse ﬂy bites an
infected mammalian host, these non-proliferative, stumpy
parasites are taken up by the ﬂy and transform into
proliferating procyclic forms in the ﬂy midgut. Parasites
then migrate to the salivary glands of the insect where they
transform into epimastigotes that can proliferate by binary
ﬁssion. Finally, the epimastigotes transform into infective
metacyclic trypomastigotes, which are then injected into a
new mammalian host during the tsetse ﬂy’s bite.
As shown above, Chagas disease is transmitted through
the infected feces of triatomines, whereas sleeping sickness
is transmitted through the infected saliva of tsetse ﬂies.
However, other transmission modes are shared by both
species, and include transmission through blood transfu-
sions, vertical or mother-to-child transmission, and acciden-
tal infections in the laboratory.
Diagnosis is based on the presentation of clinical symp-
toms and signs, direct parasitological testing of blood or
cerebrospinal ﬂuids (in the case of T. brucei infection),
serological tests and/or by parasite DNA detection using
polymerase chainreactions (PCR).To detectT. cruzi by PCR,
samples are assayed for the presence of minicircle kinetoplast
DNA and a 195-bp reiterated DNA sequence [2, 3]. One
serological test that is used for sleeping sickness diagnosis
is the card agglutination test for trypanosomiasis (CATT);
it detects T. b. gambiense-speciﬁc antibodies [4]. For Chagas
disease, T. cruzi-speciﬁc antibodies can be detected with
assays using either crude or recombinant antigens [5, 6].
However, the use of serological tests to infer Chagas disease
cure is controversial, as antibodies against parasite antigens
can remain in circulation for long periods of time [7].
The absence or presence of mild symptoms is associated
with the chronic phases of both diseases. However, the acute
symptoms of Chagas disease can be diagnosed by a trained
physician and include swelling, nausea, diarrhea, vomiting,
liver or spleen enlargement, fever, headaches, and chest or
abdominal pain. About 40% of patients develop chronic
disease with heart or colon dilation after 10–20 years of
infection. Similarly, sleeping sickness is also characterized by
two distinct stages. In the acute phase or hemolymphatic
stage, symptoms include headache, malaise, weight loss,
fatigue, fever, and vomiting. In the second phase, also known
as the neurological phase, parasites are present within the
cerebral spinal ﬂuid and brain and cause many neurological
andphysiatricsymptoms includinganxiety,disruptionofthe
sleep-wake cycle, behavior changes, and motor features such
as muscle tremors and walking diﬃculties [8]. If untreated,
sleeping sickness is fatal. In the absence of treatment, it is
estimated that T. b. gambiense infection is fatal within three
years [9]an dthatT. b. rhodesiense infection is fatal within six
to eight months [10, 11].
Drugs used to treat Chagas disease and sleeping sickness
have undesired toxic side eﬀects and are not eﬀective against
all parasite life cycle stages or parasite strains because of
drug resistance. However, eﬀective drugs exist to treat
the acute phases of both diseases. Despite the presence of
numerous side eﬀects, benznidazole (BNZ) (N-benzyl-2-
nitroimidazole-1-acetamide) and nifurtimox (NF) (4-([5-
nitrofurfuryledene]amino)-3-methylthiomorpholine-1,1
dioxide) are eﬀective against Chagas disease. Both were
introduced into clinical use in the 1970’s [12]. While NF
increases the production of free radicals believed to cause
trypanosome death [13, 14], BNZ disrupts protein synthesis
and the respiratory chain of T. cruzi (for a review see [15]).
H o w ev er ,thes edrugsar eineﬀectiveduringthechronicphase
of the disease. In the latter phases of Chagas disease, the
course of treatment is dependent on the patient’s symptoms;
m e d i c i n e so rs u r g e r ya r er e c o m m e n d e df o rp a t i e n t sw i t h
heart complications, while diet changes and possibly surgery
are suggested for patients with digestive complications.
To treat sleeping sickness, four medicines are currently
commonly used. Pentamidine and suramin are considered
ﬁrst-stage drugs. Pentamidine has been used since 1940 and
is the ﬁrst-choice drug to treat the initial stages of T. b.
gambiense infection; it is administered as an intramuscular
injection. The exact antiprotozoal mechanisms of action
of pentamidine are still unknown, perhaps because it acts
against many targets including mitochondria and DNA
(reviewed at [16, 17]). Suramin has six negative charges that
allow it to interact electrostatically with many trypanosomal
enzymes, including enzymes involvedglycolysisand the pen-
tose phosphate pathway [18]. As resistance against suramin
has been observed in T. b. gambiense, suramin is currently
only used for cases of T. b. rhodesiense infection (for a review
see [16]).
More toxic that pentamidine and suramin, melarsoprol,
eﬂornithine, and a combination of eﬂornithine and NF
(for melarsoprol-refractory patients) are used to treat
patients in the neurological phase. Eﬂornithine, alpha-diﬂu-
oromethylornithine, is administered intravenously and
infusion and irreversible inhibits polyamine biosynthesis
acting at ornithine decarboxylase (EC 4.1.1.17). It is only
eﬀective against T. brucei gambiense infections [19]. In spite
of its toxic side eﬀects, melarsoprol is the most widely used
drug during the second stage of sleeping sickness; further, it
is the only drug available to treat T. b. rhodesiense infections.
Melarsoprol is derived from arsenic, and it is believed that
melarsen oxide is its active metabolite in vivo. Although it
is unknown how melarsoprol kills parasites, parasite lysis
following melarsoprol exposure was demonstrated [20].
Although there is a clear need for new drugs to treat
trypanosome-induced diseases, few drugs and clinical tri-
als have been initiated recently. The absence of standard
protocols to evaluate drug eﬃcacy and the absence of
clinical parasitological markers contribute to the diﬃculty of
launching new treatment initiatives. In the case of Chagas
disease, novel drugs with less toxic eﬀects and shorter
administration times and drugs to treat chronic disease
shouldbeprioritized.Therefore,astandardprotocolfordrug
screening against acute T. cruzi infections was proposed to
evaluate drug eﬃcacy both in in vitro and in vivo models
compared to BNZ. Although it is very important to evaluate
the eﬀect of these compounds during chronic infection, it
is not possible due to the diﬃculty in evaluating parasite
clearance using current methods [21]. Most recently, studiesEnzyme Research 3
have focused on the azolic compounds itraconazole and
posaconazole that inhibit ergosterol synthesis. In mouse
models, these drugs have been shown to cure both acute and
chronic Chagas disease [22]. In addition, posaconazole has
activity against T. cruzi both in vivo and in vivo.
Regarding sleeping sickness, new drugs should have
lower toxic side eﬀects, treat both T. b. gambiense and T. b.
rhodesiense infections, and treat late-stage T. b. rhodesiense
infection. Pafuramidine maleate (DB289) is a new drug in
clinicaltrial for thetreatment ofsleeping sickness [23].How-
ever, as it cannot cross the blood-brain barrier, it can only be
used for early stage treatment. Despite this, it has an advan-
tageoverpentamidinebecauseitcanbeorallyadministrated.
As illustrated above, the need for new drugs and novel
drug targets to treat both Chagas disease and sleeping
sickness is evident. These drugs should target fundamental
pathways within these parasites. In spite of the conserved
nature of essential pathways among eukaryotic organisms,
we identiﬁed a trypanosome prereplication machinery com-
ponentthatisfundamentalfor replicationandthatisdistinct
from eukaryotic prereplication machinery; this component
is necessary for origin selection and the establishment of
the DNA replication fork [24]. These data indicate that this
enzyme is a potential drug target for the treatment of both
Chagas disease and sleeping sickness.
2.EukaryoticPrereplicationMachinery
DNA replication in eukaryotes begins with the assembly of
the prereplication complex on regions along chromosomes
known as replication origins [25, 26]. The prereplication
complex assembly (depicted in Figure 1) begins when the
origin recognition complex (ORC), comprised of six diﬀer-
ent subunits (Orc1−6)[ 25, 27], recognizes the replication
origins and allows the recruitment of cell division cycle
Cdc6 and Cdt1 proteins to the complex. Together, the
ORC, Cdc6 and Cdt1 proteins recruit the mini-chromosome
maintenance (MCM) complex, which is comprised of six
subunits (Mcm2−7); the MCM complex harbors the helicase
activity that is essential for DNA replication [28]. Once the
prereplication machinery is bound to the replication origins,
these origins are licensed, meaning that the replication
process can initiate at these origins through the binding of
regulatory factors and DNA replication fork components
during the onset of S-phase.
3.StructuralAspectsof theORC andCdc6
PrereplicationMachinery Components
The ORC complex was ﬁrst puriﬁed from S. cerevisiae
extract as proteins that bound to replication origins [29]. S.
cerevisiae ORC (413KDa) is a heterohexamer that contains
six proteins named according their relative molecular mass:
Orc1 (120KDa), Orc2 (72KDa), Orc3 (62KDa), Orc4
(56KDa), Orc5 (53KDa), and Orc6 (50KDa). Orc1−5
orthologs were identiﬁed in a wide range of organisms,
suggesting that these genes are present in all eukaryotic
organisms. Of the six Orcs, Cdc6 is most notably similar to
(A) Mammals
ORC1-6
Cdc6
Cdt1
MCM
(B) Trypanosomatids
Orc1/Cdc6
MCM
Unknow
protein
(a) (b)
Figure 1:Schematicrepresentation oftheprereplication machinery
from mammals (A) and trypanosomatids (B). (a) and (b) indicate
the two possible mechanisms for MCM recruitment to the repli-
cation origin. (a) Orc1/Cdc6 recruits the MCM complex. (b) An
unknown protein recruits the MCM complex to the replication
origin.
Orc1 (see Figure 2). Therefore, Orc1 is more closely related
to Cdc6 than to any other ORC component [30].
Among the ORC subunits, Orc1, Orc4, and Orc5 belong
to the AAA+ family, proteins that exhibit ATPase activity
and function in multiple cellular activities [31]. Orc2 and
Orc3 contain an ATPase-like domain; Orc6 lacks the AAA+
domain and shows no structural similarity to the other
Orc proteins. The AAA+ domain contains the Walker A
and Walker B motifs and regions named sensor 1 and
sensor 2. These regions are typical in proteins that act as
“Clamp-loaders”, proteins that encircle DNA and bind other
factors and serve as processivity-promoting factors in DNA
replication in an ATP-dependent manner. Walker A and B
motifs and sensor 1 and 2 regions are responsible for ATP
binding and hydrolysis [31]; ATP binding and hydrolysis
trigger a conformational change within the ORC that allows
for the serial recruitment of proteins during prereplication
complex assembly at replication origins [32].
Cdc6 (58KDa in S. cerevisiae) was ﬁrst isolated from
thermo-sensitive mutants and identiﬁed as an important
factor during the beginning of DNA replication [33]. Cdc6
also has the AAA+ domain, containing the Walker A and
Walker B motifs and sensor 1 and 2 regions [30]. Similar to
Orc1, Cdc6 exhibits intrinsic ATPase activity in vitro [34].
4.Recruitmentofthe PrereplicationMachinery
The molecular bases that enable the recruitment of prerepli-
cation machinery have been described in yeast and they are
dependent on ATP binding and ATP hydrolysis (Figure 3).
As mentioned previously, the ﬁrst step in prereplication
machinery assembly is the binding of the ORC to the4 Enzyme Research
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Figure 2: Phylogenetic tree of human Orc1 to Orc6, human Cdc6, and Orc1/Cdc6 from Trypanosoma cruzi (Orc1Cdc6 tc), Trypanosoma
brucei (Orc1Cdc6 tb), Leishmania major (Orc1Cdc6 lm), and Methanoplanus petrolearius (orc1Cdc6 Mp), an Archaea species. The
phylogenetic tree was generated using the ClustalW alignment method.
ORC
Speciﬁc
replication origin
Cdc6
Cdt1
MCM
Cdc6 ATPase
activity
ORC ATPase
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∗
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Figure 3: Schematic representation of prereplication machinery
recruitment. Figure 3 shows that Cdc6 and ORC ATPase activities
are important for the release of these molecules from the complex.
Asterisks show the steps where ORC ATPase activity (purple ∗)o r
Cdc6 ATPase activity (orange ∗) is important for the prevention
of the assembly of the prereplication machinery at nonspeciﬁc
replication origins.
replication origins, a step that depends on the binding of
the ORC to ATP. ORC-double-stranded DNA interactions
are speciﬁc and inhibit the ATPase activity of the ORC. In
this way, the high ATPase activity of the ORC inhibits stable
ORC interactions with nonspeciﬁc DNA. However, in the
presence of a speciﬁc replication origin, the ATPase activity
of the ORC is inhibited, and it undergoes a conformational
change; the conformation change stabilizes the ORC-DNA
interaction and allows the ORC to bind Cdc6 (reviewed in
[35]). The stability of ORC-Cdc6-DNA interactions is also
regulated by the ATPase activity of Cdc6, which is high in
the presence of nonspeciﬁc DNA, destabilizing the complex
[34]. ORC-Cdc6-DNAinteractions trigger a conformational
alteration in Cdc6 that allows for the Cdc6-Cdt1 interaction
to occur[36].Therefore, theATPase activityofboththeORC
and Cdc6 work to select speciﬁc replication origins.
Once bound to DNA, the ORC and Cdc6 are able to
interact with Cdt1, which brings the MCM complex to the
replication origin. At this moment, the low activity of the
Cdc6 ATPase that is important to establish ORC-Cdc6-DNA
interaction is also required to recruit the MCM complex
onto the replication origins (reviewed in [37]). After MCM
complex recruitment, the Orc1 ATPase enables MCM-DNA
interaction [38]. Once the MCM complex is recruited and
established at the replication origins, the ORC, Cdc6 and
Cdt1 do not need to be bound to replication origin sites
any longer. At this point, prior to the activation of DNA
replication, these proteins disassociate from the replication
origins in an ATPase-dependent manner [39].
These data clearly demonstrate the extreme importance
of the ATPase activities of the diﬀerent components of the
prereplicationmachinery inthestabilization andassembly of
the prereplication machinery onto DNA replication origins.
In the selection of replication origins, the assembly of
the prereplication complex onto replication origins, the
recruitment of the MCM helicase, and in the dissociation
of the prereplication complex from the replication origins to
avoid a new round of DNA replication in the same cell cycle,
the balance between high and low ATPase activity is critical
for precise DNA replication.
5.Trypanosome Orc1/Cdc6:The
PrereplicationMachinery Component
andItsATPaseActivity
Although eukaryotic cells, trypanosomes have a prereplica-
tion machinery component that is diﬀerent from eukary-
otes and is instead closer to Archaea species. Genomic
databases of trypanosomatids show that these organisms
do not contain sequences in their genome that code for
Orc1–Orc6 subunits, Cdc6 or Cdt1. Additionally, several
Archaea sp. have one or more copies of proteins that
exhibit high sequence homology with both Orc1 and Cdc6;
these proteins are often called Orc1/Cdc6 proteins [40–42]
(Figure 2). Trypanosomatids have annotated a gene for only
one of the six subunits of the ORC, Orc1, which is also
homologous to Cdc6. It is annotated as Orc1 [43]a n dEnzyme Research 5
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Figure 4:(a)Showsthearchaea Orc1/Cdc6 structure together withATP. The AAA+ andWHdomainsareindicated. (b) Showsthepredicted
structure of T. cruzi Orc1/Cdc6, obtained using the 3D-PSSM program (http://www.sbg.bio.ic.ac.uk/∼3dpssm/index2.html).
we named it Orc1/Cdc6. In the TIGR Parasites Database
(http://www.tigr.org/), two sequences were annotated as
Orc1 (Tc00.1047053511159.20and Tc1047053508239.10)in
the genome of T. cruzi (representing gene alleles). Single
sequenceswereannotated asOrc1inthegenomesofT. brucei
(Tb11.02.5110) and T. brucei gambiense (Tbg972.11.8220).
The two Orc1 protein sequences from T. cruzi are 98.2%
identical. The Orc1sequences from T. cruzi and T. brucei are
77.1% and 77.8% identical. Trypanosome Orc1/Cdc6 was
conﬁrmedasaprereplicationmachinery componentbecause
it replaced yeast Cdc6 in a yeast phenotypic complementa-
tion assay; further, the silencing of trypanosome Orc1/Cdc6
expression by RNAinterference in T. brucei impaired nuclear
DNA replication [24].
Analyses of structural alignment using thePhyre server, a
web-based method for protein folding recognition, showed
a higher structural similarity of trypanosome Orc1/Cdc6
to archaea Orc1/Cdc6 [24]. Also, analyses of the predicted
tridimensional structure of T. cruzi Orc1/Cdc6 by 3D-
PSSM (http://www.sbg.bio.ic.ac.uk/∼3dpssm/index2.html),
which determines the most probable folds based on the
occurrence of motifs present in the secondary structure,
showed that the probable structural of T. cruzi Orc1/Cdc6
is homologous to Archaea Orc1/Cdc6 (Figure 4). These
analyses suggest that trypanosome Orc1/Cdc6 is closer to
Archaea prereplication machinery than to mammalian pre-
replication machinery. Primary sequences of trypanosome
Orc1/Cdc6 also contain Walker A and B motifs, related to
ATP/GTP binding, and sensor 1 and 2 regions that are
involved in ATP hydrolysis; these features are typical of
prereplicationmachinery componentsthatexhibittheAAA+
ATPase fold [44, 45]. In fact, both T. cruzi and T. brucei
Orc1/Cdc6 exhibit ATPase activity, which, in the presence of
increased concentrations of ATP follows a Michaelis-Menten
(MM) kinetic model. This ATPase activity increases in the
presence of nonspeciﬁc DNA [24], suggesting that, similar
to yeast, trypanosome Orc1/Cdc6 ATPase activity might
be involved in the selection of speciﬁc replication origins.
As mentioned previously, there is no Cdt1 homologous
protein in the trypanosomatid genome database. Therefore,
in these organisms, the prereplication machinery might
be assembled by the recruitment of the MCM complex
by Orc1/Cdc6. Alternatively, the prereplication machinery
could be assembled by an unknown protein that could bind
Orc1/Cdc6 and recruit the MCM complex onto the replica-
tionorigins. This assemblyschemeis depictedinFigure 1(b).
It is important to note that further studies should conﬁrm if
this schematic representation is correct. Recently, the group
of Dr. Richard McCulloch identiﬁed at least one further
ORC-like factor (pers comm.) in T. brucei. Further studies
should also be conducted to determine if Orc1/Cdc6 ATPase
activity is important for the assembly of prereplication
machinery as well as for the release of the prereplication
complex proteins from the replication origins. Nevertheless,
the silencingoftrypanosome Orc1/Cdc6expressionby RNAi
in T. brucei negative aﬀected cell survival [24]. This data
strongly indicates that Orc1/Cdc6 is extremely important for
trypanosome survivalandidentiﬁesOrc1/Cdc6asapotential
target for drug design.
6.ATPaseActivityInhibitors
Diﬀerent proteins harboring ATPase activity are being
studied as potential drug targets through the inhibition of
their ATPase activity [46–49]. The inhibition of the ATPase
activity of heat-shock protein 90 (HSP90) is a main target
for cancer treatment. HSP90 is a chaperone that acts in the
folding, stabilization, and assembly of several proteins that
are involved in many biological processes [50, 51]; further,
it is also responsible for the maintenance of cancer cells by
facilitating the function of oncoproteins allowing malignant
transformation [52]. Because HSP90 from tumor cells has
a higher activity compared to HSP90 from normal cells
[53], its inhibition eﬀects in tumor cells are higher than in
normal cells [53], making HSP90 a good target for drug
design [46, 54]. Geldanamycin, a natural compound, was the
ﬁrst compounddescribedwith antitumor eﬀectsthroughthe
inhibition of HSP90 ATPase activity [55–57]. Geldanamycin
binds to the N-terminal ATP-binding pocket of HSP90,
thereby blockingitsATPase activity [58].Sincetheseﬁndings
havebeenreported,severalstudieshavefocusedonHSP90as
a target, and several drugs such as 17-DMGA (alvespimycin)
and 17-AAG/tanespimycin have reached phase I and phase II
clinical trials, respectively [46].6 Enzyme Research
Another important health problem is antibiotic resis-
tance in the treatment of bacterial infections [59]. Diﬀerent
proteins with ATPase activity are being targeted for high-
throughput screening in order to ﬁnd new inhibitors with
potential antibiotic eﬀects. Bacterial RecA [60], DNA gyrase
[48], and essential replicative DNA helicase [49]a r es o m eo f
the ATPase proteinsupon which eﬀortis being concentrated.
RecA is a bacterial protein involved in DNA repair, which
interacts with single-stranded DNA and through its ATPase
activity allows for both recombinational DNA repair and
horizontal gene transfer, processes that are essential for the
acquisition of drug resistance genes [47]. Inhibitors of RecA
ATPase activity that act by binding the ATP-binding site
are being screened, indicating the potential development of
antibiotics capable of preventing bacterial drug resistance
[60].
DNA gyrase and the replicative DNA helicase are
proteins involved in bacterial DNA replication and are
essential for bacterial survival. Both have ATPase activity
indispensable for their function [48]. DNA gyrase is a type
II topoisomerase capable of introducing negative supercoils
during DNA replication. Although it is comprised of two
subunits (A and B), only B subunit has ATPase activity. The
aminocoumarin antibiotic class, from which novobiocin (4-
Hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)benzamido]-
8-methylcoumarin-7-yl3-O-carbamoyl-5,5-di-C-methyl-
α-l-lyxofuranoside) is licensed for treatment of human
infections, binds to the B subunit inhibiting the ATP
hydrolysis required for DNA supercoiling and preventing
cell growth [48]. The DNA replicative helicase, DNA B, is
responsible for opening double-stranded DNA through ATP
hydrolysis, which makes the DNAavailable to the replication
machinery for the duplication of the bacterial genome. Two
compounds, ﬂavonoid myricetin and triaminotriazine, are
able to inhibit the ATPase activity of DNA B helicase in
Escherichia coli and Pseudomonas aeruginosa, respectively,
preventing cell growth [49]. However, as these drugs
exhibit some cytotoxicity in mammalian cell culture, others
inhibitors are being screened as possible drug candidates
[49].
As discussed above, inhibitors of ATPase activity are
being studied as possible drugs candidates; some, such as
novobiocin, are even already being used for human treat-
ment. This raises the possibility of searching for speciﬁc in-
hibitors of T. brucei and T. cruzi Orc1/Cdc6,as these proteins
do not have a closely related protein in humans.
7.Final Considerations
In addition to its indispensable role as a DNA replica-
tion initiator, the ORC is known to aﬀect diverse cell
processes including chromosome segregation, cytokinesis,
cell cycle regulation, and gene expression [61]. It is now
time to analyze whether trypanosome Orc1/Cdc6, and its
ATPase activity are also involved in non-DNA replication
functions. If so, it would better justify additional eﬀorts
to search for an ATPase inhibitor against trypanosome
Orc1/Cdc6.
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